US 10603363
Treatment of retinitis pigmentosa using engineered meganucleases
granted A61KA61K38/465A61K48/0058
Quick answer
US patent 10603363 (Treatment of retinitis pigmentosa using engineered meganucleases) held by Precision BioSciences, Inc. expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Precision BioSciences, Inc.
- Grant date
- Tue Mar 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K38/465, A61K48/0058, A61P, A61P27/00